Boundless Bio, Inc. (BOLD)
2.63
+0.01
(+0.38%)
USD |
NASDAQ |
Oct 05, 12:23
Boundless Bio Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.559 |
| December 31, 2025 | 0.497 |
| September 30, 2025 | 0.4517 |
| June 30, 2025 | 0.4035 |
| March 31, 2025 | 0.3556 |
| December 31, 2024 | 0.3162 |
| September 30, 2024 | 0.0007 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0047 |
| March 31, 2024 | 0.0143 |
| December 31, 2023 | -1.966 |
| September 30, 2023 | -2.172 |
| June 30, 2023 | -2.437 |
| March 31, 2023 | |
| December 31, 2022 | -1.874 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
| Biogen, Inc. | 0.4433 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 73.74M |
| Total Liabilities (Quarterly) | 7.768M |
| Shareholders Equity (Quarterly) | 65.98M |
| Current Ratio | 9.481 |
| Net Debt Paydown Yield | 17.29% |